- Health at Bayer
-
Pharmaceuticals
- Treatments & Therapies
- Innovation & Technologies
- Cell and Gene Therapy
- Sustainability
- Transparency
- News & Stories
- Clinical Trials Explorer
- Transparency Policy
- Personal Health
- Report a Side Effect
- Medical Counterfeits
New Safety Features for Prescription Medicine in Europe
As of February 2019, a new European Medicines Verification System is in place with harmonized safety and control measures to prevent falsified medicines from reaching patients.
Technical implementation of the new process at Bayer’s production sites has already been completed and printing of the new verification code on prescription medicines is ongoing.

New Harmonized Safety and Control Measures
New safety features for prescription medicines will enable an end-to-end verification system to prevent falsified medicines from entering the legal supply chain. The new safety features will be mandatory in the EU Member States1 , Norway, Iceland and Liechtenstein.
How to Recognize Genuine Products
Under the European Medicines Verification System, the authenticity of medicines will be guaranteed by a so-called Data Matrix Code that incorporates an unique identifier (UI) and an anti-tampering device.
At different stages in the distribution chain, e.g. when the medicine packages reach the pharmacies, the packages will be scanned, checked and verified for authenticity. If there is an alert, the package will not be supplied and there will be an investigation to determine whether the medicine has been falsified.
As the shelf life of each product varies, it will take 3-5 years until all packages have the new safety features. Therefore, you should not be worried if your current medicine does not have the new code.

Further information
Bayer´s Commitment to Fighting Counterfeit Drugs
- 1Except Italy and Greece, which will follow later as they already have an established equivalent system in place.